Gold tops $3,000. Here’s what investors joining the gold rush need to know.

In this podcast, Motley Fool contributors Travis Hoium, Lou Whiteman, and Rachel Warren explore the potential impact of the NFL on Disney's stock performance. They also encourage listeners to access full episodes of their podcasts and consider their top 10 stock recommendations when ready to invest. Want More Context? 🔎

Retiring solely on Social Security is not advisable as benefits typically replace less than half of a worker's income, making it challenging for seniors to adjust to reduced earnings. Despite this, many seniors depend exclusively on Social Security due to difficulties in saving for retirement, heavily relying on annual cost-of-living adjustments (COLAs) for financial stability. Want More Context? 🔎

Vertex Pharmaceuticals (NASDAQ: VRTX) reported its second-quarter results, leading to a more than 17% drop in shares during early trading on Tuesday, despite the results not being poor overall. The negative investor reaction stemmed from two disappointing developments in its pipeline, which may present buying opportunities for some investors. Want More Context? 🔎

Firefly Aerospace (NASDAQ: FLY) debuted on the Nasdaq exchange on Thursday at $45, experiencing a significant rise of 34.1% to close at $60.35. However, on Friday, the company retained some gains but saw a notable decline from its initial surge. Want More Context? 🔎

Alpha Metallurgical Resources (NYSE:AMR) reported second quarter 2025 results with an adjusted EBITDA of $46.1 million from 3.9 million tons shipped, achieving a $10 per ton reduction in coal sales costs. The company improved liquidity to $557 million, restarted its share buyback program, and lowered its cost guidance, highlighting operational efficiency amidst declining met coal prices. Want More Context? 🔎

Bicycle Therapeutics Plc (NASDAQ:BCYC) reported Q2 2025 GAAP revenue of $2.9 million, significantly below the $9.43 million analyst estimate, while net loss per share widened to $(1.14), surpassing the $(0.95) forecast. Despite increased clinical investment and operational spending aimed at advancing its pipeline of precision-guided therapeutics using its proprietary Bicycle molecule platform, the company emphasized the need for operational discipline and clear milestones ahead. Want More Context? 🔎